| Name and Principal Position | | | Year | | | Salary ($) | | | Bonus ($) | | | Option Awards ($)(1) | | | Non-Equity Incentive Plan Compensation ($)(2) | | | All Other Compensation ($)(3) | | | Total ($) | | |||||||||||||||||||||
| Raymond Stevens, Ph.D. Chief Executive Officer and Director(4) | | | | | 2023 | | | | | | 595,852 | | | | | | — | | | | | | 6,500,534 | | | | | | 281,325 | | | | | | 13,200 | | | | | | 7,390,911 | | |
| | | | 2022 | | | | | | 487,333 | | | | | | — | | | | | | — | | | | | | 247,500 | | | | | | 12,500 | | | | | | 747,333 | | | ||
| Jun Yoon Chief Financial Officer(5) | | | | | 2023 | | | | | | 441,262 | | | | | | — | | | | | | 3,047,125 | | | | | | 173,183 | | | | | | 13,200 | | | | | | 3,674,770 | | |
| Mark Bach, M.D., Ph.D. Chief Medical Officer | | | | | 2023 | | | | | | 485,812 | | | | | | — | | | | | | — | | | | | | 173,045 | | | | | | 13,200 | | | | | | 672,057 | | |
| | | | 2022 | | | | | | 466,375 | | | | | | — | | | | | | — | | | | | | 149,499 | | | | | | 12,500 | | | | | | 628,374 | | | ||
| | | | Option Awards(1) | | |||||||||||||||||||||||||||
| Name | | | Grant Date | | | Number of securities underlying unexercised options (#) exercisable | | | Number of securities underlying unexercised options (#) unexercisable | | | Equity incentive plan awards: Number of securities underlying unexercised unearned options (#) | | | Option exercise price per share ($)(2) | | | Option expiration date | | ||||||||||||
| Raymond Stevens, Ph.D. Chief Executive Officer and Director | | | 1/22/2020 | | | | | 100,000(3) | | | | | | — | | | | | | — | | | | | | 0.39 | | | | 1/21/2030 | |
| | 1/22/2021 | | | | | 392,838(4) | | | | | | 145,929 | | | | | | — | | | | | | 0.48 | | | | 1/21/2031 | | ||
| | 2/2/2023 | | | | | —(5) | | | | | | 1,600,000 | | | | | | — | | | | | | 5.00 | | | | 2/1/2033 | | ||
| Jun Yoon Chief Financial Officer | | | 1/22/2020 | | | | | 100,000(6) | | | | | | — | | | | | | — | | | | | | 0.39 | | | | 1/21/2030 | |
| | 9/23/2021 | | | | | 56,238(7) | | | | | | 43,762 | | | | | | — | | | | | | 1.21 | | | | 9/22/2031 | | ||
| | 2/2/2023 | | | | | —(8) | | | | | | 750,000 | | | | | | — | | | | | | 5.00 | | | | 2/1/2033 | | ||
| Mark Bach, M.D., Ph.D. Chief Medical Officer | | | 9/23/2021 | | | | | 363,486(9) | | | | | | 218,124 | | | | | | — | | | | | | 1.21 | | | | 9/22/2031 | |
| | 2/2/2023 | | | | | — | | | | | | — | | | | | | 450,000(10) | | | | | | 5.00 | | | | 2/1/2033 | | ||
